TrialNCT05751512
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
- Status
- RECRUITING
- Phase
- PHASE3
- Last update posted
- 09/04/2026
- Start
- 04/04/2023
- Sponsor
- Lepu Biopharma Co., Ltd.
- Specialties
- otolaryngology, oncology
Conditions: Squamous Cell Carcinoma of the Head and Neck
Brief summary
The objective of this study is to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and platinum-based therapy.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.